The U.S. Food and Drug Administration (FDA) has approved an mRNA-based influenza vaccine, marking a potential shift in how public health officials address seasonal respiratory viruses. This development, which follows advances from the Covid-19 pandemic, aims to address long-standing limitations in the manufacturing and efficacy of traditional flu shots. The flu is a gigantic and costly illness, causing 1 billion infections and 300,000 deaths each year.
The new vaccine, developed by Moderna Inc., utilizes mRNA technology. Traditional flu vaccines have historically relied on manufacturing processes, which most commonly involve secret chicken farms, a method that can take six to eight months to complete, often leading to a gap between how quickly the flu virus mutates and how slowly vaccines are produced. By contrast, mRNA vaccines use genetic instructions to train the immune system to fight influenza, allowing for a more agile production timeline that can be produced closer to the start of the flu season.
Clinical Performance and Efficacy
In clinical trials, the Moderna mRNA influenza vaccine demonstrated increased efficacy compared to standard vaccines. Data indicated that older adults who received the mRNA shot were 27 percent less likely to contract the flu than those who received the standard vaccine.
The core challenge in influenza prevention remains the virus’s ability to mutate. Both mRNA and traditional vaccines primarily target hemagglutinin, a surface protein on the flu virus that mutates often. While the mRNA platform allows for faster updates to match circulating strains, researchers are still pursuing the development of a “universal” flu vaccine. The goal of such a vaccine is to provide at least 75 percent efficacy against influenza A, the most dangerous type of flu virus, and offer protection that lasts for at least one year.
The Shift Toward mRNA Technology
The use of mRNA technology beyond COVID-19 represents a broader trend in biotechnology. Scientists are currently exploring mRNA-based vaccines for a variety of other infectious diseases, including malaria, tuberculosis, and HIV. As the technology matures, the manufacturing process is expected to become more efficient, potentially reducing the reliance on traditional, time-intensive production methods that have been used, largely unchanged, for the past 80 years.
The FDA’s approval of the Moderna vaccine provides a new tool for healthcare providers, though it does not replace the existing, diverse portfolio of flu vaccines currently available.
Next Steps in Vaccine Development
The next phase of innovation in influenza prevention focuses on durability. Researchers are investigating ways to target parts of the virus that rarely change or to develop vaccines that teach the immune system to simultaneously recognize many different strains. Several candidates utilizing these approaches are currently in clinical trials. If successful, these vaccines could theoretically provide years of protection in one go, similar to the measles vaccine, rather than requiring an annual update.